ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "Assembly Biosciences, Inc." (ASMB) Report Updated: May 27, 2017 | Print This Page

Get more stock ratings by Louis Navellier

"Assembly Biosciences, Inc." (ASMB)

Rating: Buy Volatility: Aggressive
Total Grade: B Industry: Pharmaceuticals
Competitors: HSKA,HCM,AERI,PAHC

Stock Analysis

Rating: Monthly View

A
B
C
D
F
May June July August September October November December January February March April

Rating: Weekly View

This Week: B down downgrade
Last Week: A same no change
Two Weeks Ago: A up no change
service keys

"Assembly Biosciences, Inc."© quotemedia

Company Profile

Assembly Biosciences, Inc., a biopharmaceutical company, develops oral therapies for intractable infectious diseases in the United States. The company focuses on the hepatitis B virus (HBV) and C. difficile-associated infections (CDAD). It is involved in developing core protein allosteric modulators that modulate the HBV core protein, a polyfunctional viral protein, at various complementary points in the viral lifecycle; and microbiome program, a treatment for CDAD, for targeted delivery of complex agents to select regions of the gastrointestinal tract. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in New York, New York.